 World News
 USA (196)
 Bay Area
 San Francisco (1270)
North San Mateo County (138)
South SF (87)
 Accidents (32)
 Politics (4)
 Crime (32)
 Business (37)
 Sports
 Science & Education (10)
 Business
 Bio Tech (21)
 Business Lawsuit (2)
 Earnings (8)
 Public Transportation (2)
 Merger (1)
 Commercial Real Estate (1)
 Business Leaders (1)
 Retail (1)
2007 (7)
2006 (14)
2005 (5)
2004 (4)
2003 (2)
2002 (2)
Genentech
 South SF Business on Wikipedia
 South SF Business on Web
 South SF Business Books
 Real Estate
 Chart
|
| South SF, Business Timeline Legend |
|
| Retail
|
|
|
| Apr.30 |
|
Bad news on cancer drug Rituxan| Genentech: Shares in Genentech sagged, after the company said Rituxan failed to curb symptoms of the debilitating autoimmune disorder | |
|
| Apr.24 |
|
Court slashes $200 million from judgment| Genentech: The company has been ordered to pay $500 million to a Southern California hospital for failing to pay royalties | |
|
|
| Feb.22 |
|
FDA Clears Avastin for Breast Cancer| Genentech: A Genentech drug received federal approval, a surprise decision | | |
|
| Feb.17 |
|
Prostate cancer vaccine shows promise Shares in Cell Genesys shot up nearly 20% after the company released a favorable analysis of its experimental prostate cancer vaccine GVAX
|
|
| Jan.14 |
|
4Q Profit Rises 6 Percent Genentech: The biotech giant barely scraped past expectations as stock dropped in after-hours trading as sales of a key product also fell below expectations
|
| Jan.10 |
|
City approved design for ferry terminal Ferry service between Oyster Point and Jack London Square in Oakland could begin by the end of 2009
|
|
| Dec.5 |
|
FDA Panel Rejects Avastin, stock drops| Genentech: Shares dropped nearly 9% after a panel of medical experts said FDA should deny approval of the company's blockbuster drug | |
|
| Oct.16 |
|
3Q Profit Up 21 % On Cancer Drug Sales Genentech: The profit rose nearly 21% from a year ago, beating expectations by a penny thanks to stronger-than-expected sales of the Avastin
|
| Aug.3 |
|
Genentech completes Tanox acquisition
|
| Apr.11 |
|
Funds For South S.F.-Oakland Ferry Metropolitan Transportation Commission funds for the project approved of $300,000
|
| Mar.24 |
|
Genentech projects quarter to be 'flat'
|
| |
Queen Mary 2 Arrives
|
| Jan.10 |
|
4Q Earnings Soar 75% Genentech: A strong demand for cancer-fighting drugs fueled a profit increase as company executives shook off doubts
|
|
| Dec.21 |
|
Genentech gets rights to drug
|
| Nov.11 |
|
Genentech to acquire partner Tanox Genentech Inc. has agreed to its first acquisition ever - Tanox Inc., co-developer of the asthma medicine Xolair
|
| Sep.12 |
|
Avastin approval slowed by FDA. Genentech
|
| Aug.12 |
|
Cancer drug review extended Genentech: FDA has extended by up to 90 days its review of Herceptin for treatment of patients with breast cancer.
|
| Aug.8 |
|
Genentech has plans to expand
|
| Jul.31 |
|
Tony Blair Visits Genentech Headquarters Heavy hitters from biotech firms sat down for an extraordinary talk with British Prime Minister
|
| Jul.11 |
|
2Q Profit Soars to $531 Million Genentech: The biotechnology company blew past Wall Street expectations with a 79% surge in second quarter earnings
|
| Jul.1 |
|
FDA approves blindness drug Genentech: Genentech Inc. won approval to market Lucentis, to restore sight in patients afflicted with a common eye disease
|
| Jun.29 |
|
2 drugs set to fight blindness. Genentech
|
| Apr.12 |
|
Profit climbs by 48% in first quarter Genentech: Genentech Inc. raised its full-year earnings growth estimate to as much as 55% over 2005
|
| Feb.13 |
|
Cancer Drug Trials Scaled Back Genentech: Avastin only targets cancer, and leaves healthy cells alone
|
| |
Mayor Accuses Conductors Of Stealing
|
| Jan.15 |
|
CEO at See's retires after 55-year career Charles Huggins was hired in 1951 by Laurance and Harry See as an administrative assistant trainee
|
| Jan.11 |
|
Up 64% in quarter after good year Genentech: Earnings per share grew 63 percent to 31 cents as cancer drugs continued to build sales
|
|
| Jul.11 |
|
Profits Soar 73% in 2Q Genentech: The second quarter profit is fueled by continued strong drug sales. The results exceeded the estimate by 4 cents
|
| Apr.16 |
|
Avastin helps those with breast cancer. Genentech
|
| Apr.12 |
|
Biotech giant's profit up 61%. Genentech
|
| Jan.10 |
|
4th best place to work for in U.S.. Genentech
|
| |
|
Profit surges, misses expectations by 1c. Genentech
|
|
| Nov.29 |
|
Avastin helps sickest patients. Genentech
|
| Oct.6 |
|
Profits surge on drug sales. Genentech
|
| Apr.7 |
|
Profits surge on brisk cancer drug sales. Genentech
|
| Feb.26 |
|
FDA approves cancer fighter Avastin. Genentech
|
|
| |
BART Begins Service To SFO
|
| May.19 |
|
Encouraging results with cancer drug| Genentech: Avastin extended the lives of some of the colon cancer patients. Company's stock soaring nearly 45% | |
|
|
| Sep.7 |
|
Big patent win vs. Chiron Genentech: Chiron of Emeryville has no claim to any profits from Genentech's blockbuster breast cancer drug, Herceptin
|
| Aug.26 |
|
Lotto winner stepped forward The 43-year-old grandmother Cindy Blair will share the $120 million-dollar pot with three other winners
| South SF, Business | Major Events in 21st Century | 
|
|
Neighbor  Real Estate:
Add a favorite (file a bookmark) to South SF, Business Timeline
Please send feedback to: support@mapreport.com
Advertise on South SF, Business Page
|
|
| 2008 |
|
| Apr.24 |
Court slashes $200 million from judgment| Genentech: The company has been ordered to pay $500 million to a Southern California hospital for failing to pay royalties | |
| 2002 |
|
| Sep.7 |
Big patent win vs. Chiron Genentech: Chiron of Emeryville has no claim to any profits from Genentech's blockbuster breast cancer drug, Herceptin
|
|
| 2002 |
|
| Aug.26 |
Lotto winner stepped forward The 43-year-old grandmother Cindy Blair will share the $120 million-dollar pot with three other winners
|
|
| 2006 |
|
| Nov.11 |
Genentech to acquire partner Tanox Genentech Inc. has agreed to its first acquisition ever - Tanox Inc., co-developer of the asthma medicine Xolair
|
|
| 2008 |
|
| Jan.10 |
City approved design for ferry terminal Ferry service between Oyster Point and Jack London Square in Oakland could begin by the end of 2009
| 2007 |
|
| Apr.11 |
Funds For South S.F.-Oakland Ferry Metropolitan Transportation Commission funds for the project approved of $300,000
|
|
| 2006 |
|
| Jan.15 |
CEO at See's retires after 55-year career Charles Huggins was hired in 1951 by Laurance and Harry See as an administrative assistant trainee
|
|
| 2008 |
|
| Apr.30 |
Bad news on cancer drug Rituxan| Genentech: Shares in Genentech sagged, after the company said Rituxan failed to curb symptoms of the debilitating autoimmune disorder | |
|
| Feb.22 |
FDA Clears Avastin for Breast Cancer| Genentech: A Genentech drug received federal approval, a surprise decision | | |
|
| Feb.17 |
Prostate cancer vaccine shows promise Shares in Cell Genesys shot up nearly 20% after the company released a favorable analysis of its experimental prostate cancer vaccine GVAX
| 2007 |
|
| Dec.5 |
FDA Panel Rejects Avastin, stock drops| Genentech: Shares dropped nearly 9% after a panel of medical experts said FDA should deny approval of the company's blockbuster drug | |
|
| Aug.3 |
Genentech completes Tanox acquisition
|
| Mar.24 |
Genentech projects quarter to be 'flat'
| 2006 |
|
| Dec.21 |
Genentech gets rights to drug
|
| Sep.12 |
Avastin approval slowed by FDA. Genentech
|
| Aug.12 |
Cancer drug review extended Genentech: FDA has extended by up to 90 days its review of Herceptin for treatment of patients with breast cancer.
|
| Jul.31 |
Tony Blair Visits Genentech Headquarters Heavy hitters from biotech firms sat down for an extraordinary talk with British Prime Minister
|
| Jul.11 |
2Q Profit Soars to $531 Million Genentech: The biotechnology company blew past Wall Street expectations with a 79% surge in second quarter earnings
|
| Jul.1 |
FDA approves blindness drug Genentech: Genentech Inc. won approval to market Lucentis, to restore sight in patients afflicted with a common eye disease
|
| Jun.29 |
2 drugs set to fight blindness. Genentech
|
| Feb.13 |
Cancer Drug Trials Scaled Back Genentech: Avastin only targets cancer, and leaves healthy cells alone
| 2005 |
|
| Jul.11 |
Profits Soar 73% in 2Q Genentech: The second quarter profit is fueled by continued strong drug sales. The results exceeded the estimate by 4 cents
|
| Apr.16 |
Avastin helps those with breast cancer. Genentech
|
| Jan.10 |
4th best place to work for in U.S.. Genentech
| 2004 |
|
| Nov.29 |
Avastin helps sickest patients. Genentech
|
| Oct.6 |
Profits surge on drug sales. Genentech
|
| Feb.26 |
FDA approves cancer fighter Avastin. Genentech
| 2003 |
|
| May.19 |
Encouraging results with cancer drug| Genentech: Avastin extended the lives of some of the colon cancer patients. Company's stock soaring nearly 45% | |
|
|
| 2006 |
|
| Aug.8 |
Genentech has plans to expand
|
|
| 2008 |
|
| Jan.14 |
4Q Profit Rises 6 Percent Genentech: The biotech giant barely scraped past expectations as stock dropped in after-hours trading as sales of a key product also fell below expectations
| 2007 |
|
| Oct.16 |
3Q Profit Up 21 % On Cancer Drug Sales Genentech: The profit rose nearly 21% from a year ago, beating expectations by a penny thanks to stronger-than-expected sales of the Avastin
|
| Jan.10 |
4Q Earnings Soar 75% Genentech: A strong demand for cancer-fighting drugs fueled a profit increase as company executives shook off doubts
| 2006 |
|
| Apr.12 |
Profit climbs by 48% in first quarter Genentech: Genentech Inc. raised its full-year earnings growth estimate to as much as 55% over 2005
|
| Jan.11 |
Up 64% in quarter after good year Genentech: Earnings per share grew 63 percent to 31 cents as cancer drugs continued to build sales
| 2005 |
|
| Apr.12 |
Biotech giant's profit up 61%. Genentech
|
| Jan.10 |
Profit surges, misses expectations by 1c. Genentech
| 2004 |
|
| Apr.7 |
Profits surge on brisk cancer drug sales. Genentech
|
Business Lawsuit Timeline
... See 
Retail Timeline
... See 
Merger Timeline
... See 
Public Transportation Timeline
... See 
Business Leaders Timeline
... See 
Bio Tech Timeline
... See 
Commercial Real Estate Timeline
... See 
Earnings Timeline
... See